PDIA4 and obesity disorder: These new treatments include: (1) Setmelanotide—an MC4R agonist used to treat genetically-stimulated obesity and (2) Pdia4 inhibitor (GHTT)—a drug used to improve pancreatic β-cell function in diabetic patients.